Odonate Therapeutics Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Odonate Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ODT, but not buy additional shares or sell existing shares.
View analyst ratings for Odonate Therapeutics or view top-rated stocks.

Wall Street analysts have given Odonate Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Odonate Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Odonate Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,860,000 shares, an increase of 67.6% from the March 31st total of 1,110,000 shares. Based on an average trading volume of 4,120,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 6.2% of the company's shares are sold short.
View Odonate Therapeutics' Short Interest.

Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 11th 2021.
View our earnings forecast for Odonate Therapeutics.

Odonate Therapeutics, Inc. (NASDAQ:ODT) released its earnings results on Tuesday, February, 23rd. The company reported ($0.87) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.78) by $0.09.
View Odonate Therapeutics' earnings history.

Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ODT shares have decreased by 88.2% and is now trading at $3.06.
View which stocks have been most impacted by COVID-19.

5 equities research analysts have issued twelve-month price objectives for Odonate Therapeutics' shares. Their forecasts range from $4.00 to $50.00. On average, they anticipate Odonate Therapeutics' stock price to reach $19.33 in the next twelve months. This suggests a possible upside of 531.8% from the stock's current price.
View analysts' price targets for Odonate Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Odonate Therapeutics include Spectrum Pharmaceuticals (SPPI), Avadel Pharmaceuticals (AVDL), GT Biopharma (GTBP), Viking Therapeutics (VKTX), Akouos (AKUS), Provention Bio (PRVB), Sesen Bio (SESN), Applied Therapeutics (APLT), AC Immune (ACIU), TherapeuticsMD (TXMD), ANI Pharmaceuticals (ANIP), Forte Biosciences (FBRX), Geron (GERN), MedAvail (MDVL) and Nature's Sunshine Products (NATR).
View all of ODT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), The Boeing (BA), Bausch Health Companies (BHC), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), AbbVie (ABBV), Apellis Pharmaceuticals (APLS), Athenex (ATNX), BioCryst Pharmaceuticals (BCRX) and CRISPR Therapeutics (CRSP).

(ODT) raised $150 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager.

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Odonate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.09%), Virginia Retirement Systems ET AL (0.05%) and First Midwest Bank Trust Division (0.03%). Company insiders that own Odonate Therapeutics stock include Aaron I Davis, Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang.
View institutional ownership trends for Odonate Therapeutics.

ODT stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A..
View insider buying and selling activity for Odonate Therapeutics or view top insider-selling stocks.

ODT stock was acquired by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, and Virginia Retirement Systems ET AL. Company insiders that have bought Odonate Therapeutics stock in the last two years include Aaron I Davis, Boxer Capital, Llc, Jeff L Vacirca, and Kevin C Tang.
View insider buying and selling activity for Odonate Therapeutics or or view top insider-buying stocks.

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ODT stock can currently be purchased for approximately $3.06.

Odonate Therapeutics has a market capitalization of $118.13 million. The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis.

Odonate Therapeutics employs 134 workers across the globe.

The official website for Odonate Therapeutics is www.odonate.com.

Odonate Therapeutics is headquartered at 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121.

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at (858) 731-8180 or via email at [email protected]